CELC Celcuity Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1603454 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-28.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,192.9%
ROA-42.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets110.2%
Debt / equity—
Current ratio14.62x
Interest coverage-11.94x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $145.00M | $104.20M | $60.59M | $35.29M | $25.76M |
| SG&A expense | $27.20M | $9.06M | $5.64M | $4.10M | $2.60M |
| Operating income | -$172.19M | -$113.27M | -$66.23M | -$39.39M | -$28.36M |
| Interest expense | $17.15M | $10.28M | $5.33M | $2.11M | $1.26M |
| Pretax income | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -$29.61M |
| Net income | -$177.04M | -$111.78M | -$63.78M | -$40.37M | -$29.61M |
| EBITDA | -$172.03M | -$113.14M | -$66.09M | -$39.18M | -$28.05M |
| EPS (basic) | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 |
| EPS (diluted) | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 |
| Weighted avg. shares (diluted) | 46.76M | 39.45M | 23.68M | 15.42M | 13.38M |
| Balance sheet | |||||
| Cash & equivalents | $165.70M | $22.52M | $30.66M | $24.57M | $84.29M |
| Short-term investments | $275.79M | $212.59M | $149.92M | $144.02M | — |
| Current assets | $465.66M | $244.57M | $190.59M | $175.19M | $85.35M |
| PP&E, net | $499,000 | $336,000 | $228,782 | $260,294 | $312,444 |
| Total assets | $466.56M | $245.12M | $191.22M | $175.70M | $85.91M |
| Current liabilities | $44.15M | $31.72M | $14.19M | $6.88M | $2.51M |
| Long-term debt | $137.55M | $105.09M | $37.57M | $35.76M | $15.98M |
| Total debt | $137.55M | $105.09M | $37.57M | $35.76M | $15.98M |
| Total liabilities | $366.00M | $129.50M | $51.45M | $41.93M | $17.20M |
| Shareholders' equity | $100.56M | $115.62M | $139.77M | $133.77M | $68.71M |
| Net debt | -$28.16M | $82.58M | $6.90M | $11.18M | -$68.31M |
| Shares outstanding | 48.24M | 37.14M | 25.51M | 21.67M | 14.92M |
| Cash flow statement | |||||
| Operating cash flow | -$153.28M | -$83.47M | -$53.81M | -$36.01M | -$20.31M |
| Capital expenditure | $249,000 | $250,000 | $97,644 | $158,768 | $81,898 |
| Free cash flow | -$153.53M | -$83.72M | -$53.91M | -$36.17M | -$20.39M |
| Investing cash flow | -$64.08M | -$63.07M | -$5.01M | -$144.03M | -$81,398 |
| Financing cash flow | $360.55M | $138.39M | $64.91M | $120.33M | $93.04M |
| Depreciation & amortization | $167,000 | $130,000 | $142,772 | $210,918 | $303,235 |
| Stock-based compensation | $21.38M | $6.99M | $4.90M | $4.64M | $2.61M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.